Quince Therapeutics, Inc.QNCXNASDAQ
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank77
3Y CAGR-38.7%
5Y CAGR-1.5%
Year-over-Year Change
Year-over-year operating cash flow growth rate
3Y CAGR
-38.7%/yr
vs +59.2%/yr prior
5Y CAGR
-1.5%/yr
Recent deceleration
Acceleration
-97.9pp
Decelerating
Percentile
P77
Within normal range
vs 5Y Ago
0.9x
Contraction
Streak
2 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q3 2025 | 13.03% |
| Q2 2025 | -18.89% |
| Q1 2025 | -27.13% |
| Q4 2024 | -4.02% |
| Q3 2024 | 16.92% |
| Q2 2024 | -4.62% |
| Q1 2024 | -37.43% |
| Q4 2023 | -26.15% |
| Q3 2023 | -25.89% |
| Q2 2023 | -7.23% |
| Q1 2023 | 38.83% |
| Q4 2022 | 12.87% |
| Q3 2022 | 56.56% |
| Q2 2022 | 4.20% |
| Q1 2022 | -11.60% |
| Q4 2021 | 16.86% |
| Q3 2021 | 1.25% |
| Q2 2021 | -29.04% |
| Q1 2021 | -2.52% |
| Q4 2020 | -7.32% |
| Q3 2020 | 14.04% |
| Q2 2020 | -33.52% |
| Q1 2020 | 1.56% |
| Q4 2019 | -24.49% |
| Q3 2019 | -39.29% |
| Q2 2019 | 12.49% |
| Q1 2019 | -81.63% |
| Q4 2018 | -106.39% |
| Q3 2018 | 26.53% |
| Q2 2018 | 17.53% |
| Q1 2018 | 0.00% |